Cover Image
市場調查報告書

Pharnext SAS : 產品平台分析

Pharnext SAS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251705
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Pharnext SAS : 產品平台分析 Pharnext SAS - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 25 Pages
簡介

Pharnext SAS是總公司設立於法國的生物製藥企業,正在研究開發並商品化進行性神經性腓骨萎縮症及老年癡呆症治療藥。利用以網路生物學為基礎的藥物研發平台,配合以特性相關之錯體分子重建之研究。

本報告提供Pharnext SAS 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Pharnext SAS 基本資料

  • Pharnext SAS 概要
  • 主要資訊
  • 企業資料

Pharnext SAS :R&D概要

  • 主要的治療範圍

Pharnext SAS :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Pharnext SAS :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Pharnext SAS :藥物簡介

  • (acamprosate calcium + baclofen)
  • (baclofen + naltrexone + sorbitol)
  • Drug 1 for Type 2 Diabetes

Pharnext SAS :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Pharnext SAS:最近的開發平台形勢

Pharnext SAS:開發暫停中的計劃

Pharnext SAS:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07532CDB

Summary

Global Markets Direct's, 'Pharnext SAS - Product Pipeline Review - 2015', provides an overview of the Pharnext SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharnext SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharnext SAS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharnext SAS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharnext SAS's pipeline products

Reasons to buy

  • Evaluate Pharnext SAS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharnext SAS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharnext SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharnext SAS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharnext SAS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharnext SAS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharnext SAS Snapshot
    • Pharnext SAS Overview
    • Key Information
    • Key Facts
  • Pharnext SAS - Research and Development Overview
    • Key Therapeutic Areas
  • Pharnext SAS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Pharnext SAS - Pipeline Products Glance
    • Pharnext SAS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Pharnext SAS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Pharnext SAS - Drug Profiles
    • (acamprosate calcium + baclofen)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (baclofen + naltrexone + sorbitol)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug 1 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharnext SAS - Pipeline Analysis
    • Pharnext SAS - Pipeline Products by Target
    • Pharnext SAS - Pipeline Products by Route of Administration
    • Pharnext SAS - Pipeline Products by Molecule Type
    • Pharnext SAS - Pipeline Products by Mechanism of Action
  • Pharnext SAS - Recent Pipeline Updates
  • Pharnext SAS - Dormant Projects
  • Pharnext SAS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharnext SAS, Key Information
  • Pharnext SAS, Key Facts
  • Pharnext SAS - Pipeline by Indication, 2015
  • Pharnext SAS - Pipeline by Stage of Development, 2015
  • Pharnext SAS - Monotherapy Products in Pipeline, 2015
  • Pharnext SAS - Combination Treatment Modalities in Pipeline, 2015
  • Pharnext SAS - Phase II, 2015
  • Pharnext SAS - Phase I, 2015
  • Pharnext SAS - Preclinical, 2015
  • Pharnext SAS - Pipeline by Target, 2015
  • Pharnext SAS - Pipeline by Route of Administration, 2015
  • Pharnext SAS - Pipeline by Molecule Type, 2015
  • Pharnext SAS - Pipeline Products by Mechanism of Action, 2015
  • Pharnext SAS - Recent Pipeline Updates, 2015
  • Pharnext SAS - Dormant Developmental Projects,2015

List of Figures

  • Pharnext SAS - Pipeline by Top 10 Indication, 2015
  • Pharnext SAS - Pipeline by Stage of Development, 2015
  • Pharnext SAS - Combination Treatment Modalities in Pipeline, 2015
  • Pharnext SAS - Pipeline by Top 10 Target, 2015
  • Pharnext SAS - Pipeline by Top 10 Route of Administration, 2015
  • Pharnext SAS - Pipeline by Top 10 Molecule Type, 2015
  • Pharnext SAS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top